(Q33358095)

26 July 2017

1 reference

title

Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood (English)

1 reference

26 July 2017

1 reference

1 reference

3

Marc Ladanyi

1 reference

26 July 2017

E Anders Kolb

1

1 reference

26 July 2017

Qiulu Pan

series ordinal

2

1 reference

26 July 2017

Peter G Steinherz

series ordinal

4

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

98

1 reference

26 July 2017

issue

12

1 reference

26 July 2017

page(s)

2643-2650

1 reference

Philadelphia chromosome-positive chronic myelocytic leukemia in children. Survival and prognostic factors

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Comparison of a multiplex reverse transcriptase-polymerase chain reaction for BCR-ABL to fluorescence in situ hybridization, Southern blotting, and conventional cytogenetics in the monitoring of patients with Ph1-positive leukemias.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Granulocyte colony-stimulating factor regulates myeloid differentiation through CCAAT/enhancer-binding protein epsilon

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11895

7 January 2021

Identifiers

DOI

10.1002/CNCR.11895

1 reference

26 July 2017

1 reference